Drugs / Romiplostim N01
last change 3 days ago re-read 2 minutes ago

Romiplostim N01

Peptide targets MPL via activation

Developed for
thrombocytopenia · aplastic anemia · autoimmune thrombocytopenia · cancer · acute myeloid leukemia · disease related to hematopoietic stem cell transplant · idiopathic aplastic anemia · myelodysplastic syndrome
Investigated by
Institute of Hematology & Blood Diseases Hospital, China · Peking Union Medical College Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Tianjin Medical University Cancer Institute and Hospital · Affiliated Hospital of Nantong University · Changzhi Medical College
+32 more · China-Japan Union Hospital, Sun Yat-sen University Cancer Center · Hebei Medical University Fourth Hospital · Henan Provincial People's Hospital · North China University of Science and Technology · Peking University Cancer Hospital and Institute · Peking University International Hospital · Peking University People's Hospital · Qilu Pharmaceutical Co., Ltd. · Shanxi Province Cancer Hospital · Shenzhen Second People's Hospital · The Affiliated Hospital of Qingdao University · The First Affiliated Hospital of Bengbu Medical University · The First Affiliated Hospital of Soochow University · The Second Affiliated Hospital of Dalian Medical University · The Second Affiliated Hospital of Kunming Medical University · Weifang People's Hospital · Affiliated Hospital of North Sichuan Medical College · Baoding First Central Hospital · First Affiliated Hospital of Zhejiang University · Guizhou Provincial People's Hospital · Henan Cancer Hospital · Jun Wang · Qilu Hospital of Shandong University · Shandong University · Suining Central Hospital · The First People's Hospital of Yunnan · Tianjin Hospital of ITCWM-Nankai Hospital · Tianjin Medical University Second Hospital · Tianjin People's Hospital · Tianjin Third Central Hospital · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Zhujiang Hospital

Trials 19 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07321626 Jun 2025 → Dec 2027 expected acute myeloid leukemia, disease related to hematopoietic stem cell transplant, myelodysplastic syndrome First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
Phase 214 trials
Phase 2 NCT07523009 Jun 2026 → Dec 2028 aplastic anemia Peking Union Medical College Hospital Withdrawn No outcome recorded
Phase 2 NCT07532408 Jun 2026 → Dec 2028 aplastic anemia Peking Union Medical College Hospital Withdrawn No outcome recorded
Phase 2 NCT07400250 Apr → Oct 2026 expected autoimmune thrombocytopenia Peking Union Medical College Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07558434 Apr 2026 → Dec 2028 expected aplastic anemia Peking Union Medical College Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07572084 Apr 2026 → Dec 2028 expected aplastic anemia Peking Union Medical College Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07043894 Dec 2025 → Sep 2026 expected cancer, hematopoietic and lymphoid cell neoplasm, thrombocytopenia Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting No outcome recorded
Phase 2 NCT07586826 Dec 2025 → Oct 2027 expected breast cancer, cervical cancer, fallopian tube cancer, non-small cell lung carcinoma +3 Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT07586813 Dec 2025 → Oct 2027 expected colorectal cancer, malignant pancreatic neoplasm, thrombocytopenia Peking University People's Hospital Recruiting No outcome recorded
Phase 2 NCT07128576 Sep 2025 → Aug 2027 expected cancer Zhujiang Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07063225 Aug 2025 → Aug 2026 overdue thrombocytopenia Institute of Hematology & Blood Diseases Hospital, China Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT07345000 Jan 2026 → Oct 2029 expected idiopathic aplastic anemia Qilu Pharmaceutical Co., Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT06440824 Jun 2024 → Jun 2025 thrombocytopenia Shandong University Unknown No outcome recorded
Phase not applicable2 trials
NCT07206823 Sep 2025 → Feb 2027 expected autoimmune thrombocytopenia The First Affiliated Hospital of Soochow University Recruiting No outcome recorded
NCT07185893 Sep 2025 → Mar 2028 expected cancer, thrombocytopenia Jun Wang Not yet recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as Romiplostim N01 Romiplostim N01, starting dose of 1 µg/kg, subcutaneous injection, given on the third day of IVIG, once a week, for up to one month.” NCT06686927
18

NCT07586826

NCT07043894

NCT06992128

NCT07523009

NCT06613880

NCT07185893

NCT07586813

NCT07572084

NCT06658834

NCT07321626

NCT07345000

NCT06440824

NCT07558434

NCT07128576

NCT07400250

NCT07063225

NCT07532408

NCT07206823

Action Activate activate them” NCT06613880
Modality Peptide “Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow” NCT06613880
Route Subcutaneous subcutaneous injection” NCT06440824
Target MPL “both romiplostim and eltrombopag/hyrtiopeg activate the TPO receptor (c-Mpl)” NCT07523009